EACH YEAR MORE than 600,000 people in this country die from coronary artery disease. It has been estimated that more than half of this number could be saved and returned to a productive life through the prompt application of either temporary or permanent forms of mechanical circulatory assistance (MCA).' Such a projection presumes that a means to detect life-threatening events can be devised and that effective devices to support the circulation can be fabricated. In the former instance, identification and delivery of patients at risk to treatment centers must await the development of a comprehensive health care system based on public education, triage centers, and sophisticated technology capable of predicting or detecting potentially serious cardiac events. By contrast, the methodology to support the failing circulation on a temporary basis is already a reality and has been since the cardiopulmonary-bypass machine was first used successfully for open-heart surgery in 1953.2 However, because of extensive bloodelement destruction accompanying prolonged use, cardiopulmonary bypass has been limited to a time frame exceeding no more than a few hours.3 To circumvent this limitation and also to explore new approaches with equal effec-
EACH YEAR MORE than 600,000 people in this country die from coronary artery disease. It has been estimated that more than half of this number could be saved and returned to a productive life through the prompt application of either temporary or permanent forms of mechanical circulatory assistance (MCA).' Such a projection presumes that a means to detect life-threatening events can be devised and that effective devices to support the circulation can be fabricated. In the former instance, identification and delivery of patients at risk to treatment centers must await the development of a comprehensive health care system based on public education, triage centers, and sophisticated technology capable of predicting or detecting potentially serious cardiac events. By contrast, the methodology to support the failing circulation on a temporary basis is already a reality and has been since the cardiopulmonary-bypass machine was first used successfully for open-heart surgery in 1953.2 However, because of extensive bloodelement destruction accompanying prolonged use, cardiopulmonary bypass has been limited to a time frame exceeding no more than a few hours. 3 To circumvent this limitation and also to explore new approaches with equal effec- tiveness and greater applicability, new assist devices have been developed, tested experimentally, and, in some instances, used in man.4-29 Some of these devices have been no more than an evolutionary step in the continuing development of MCA and have now been discarded.'" 27 Others, like the cardiopulmonary-bypass machine, have undergone refinements but have persisted largely unchanged from their original design. All devices at present, however, must be considered only a means for temporary circulatory assistance; as yet no device has been fabricated with the capability of assisting and sustaining the circulation permanently.
This article will attempt to put the rapidly growing and changing field of MCA into some perspective. In particular, the goals of MCA will be described, the physiologic principles employed in its application and indications for its use will be discussed, and the current status of the various methods will be reviewed. Furthermore, our own experience in combining MCA with emergency coronary angiography and myocardial revascularization will be reported.
Physiologic Basis of MCA
The development of the various methods of MCA has been based on three well-known physiologic principles: (1) decreased preload; (2) diminished afterload (decreased aortic impedance); and (3) direct cardiac compression. Both (1) and (2) exert a major portion of their effect by reducing left ventricular diastolic volume, thus leading to decrease in developed intramyocardial tension and a diminution in myocardial oxygen consumption (MV0). The individual devices classified according to the physiologic principles upon which each is based are shown in table 1 . It is to be noted that those devices which diminish afterload usually have the added effect of increasing diastolic arterial (and coronary) perfusion pressure. Other devices are a hybrid, combining both the effects of diminished preload and afterload.
Decreased preload may be accomplished by diversion or shunting of blood away from the left ventricle so that the device operates "in parallel" with the heart, thus making it effective in the presence of ventricular fibrillation or standstill. The standard cardiopulmonary bypass machine is the classical means of decreasing preload, although the same effect may be achieved through shunting blood from left atrium (LA) or left ventricle (LV) to aorta or peripheral artery. With the latter approach the lungs of the patient are used to oxygenate the blood; furthermore, reduction in left-sided filling pressures by the bypass pump Identical effects on the circulation may be obtained using a nonocclusive intraaortic balloon pump. 5 15, 21 At the beginning of diastole, balloon inflation increases diastolic arterial pressure and promotes runoff of blood to the periphery and at least theoretically back into the coronary arteries. The balloon is deflated just prior to the onset of the next ventricular systole so that the left ventricle ejects its contents into an aorta relatively emptied of blood by the previous balloon systole; hence left ventricular peak systolic pressure is lowered ( fig. 1 ). Direct cardiac compression13 needs no explanation, since the approach is identical to that employed by direct cardiac massage. 8 9 a mechanical auxiliary ventricle,9 the intraaortic balloon-pump system,.' 13, 21 31 external regional pressure variation,'0' 25 and most recently the dynamic aortic patch which is designed to be implanted permanently. 29 Although most of these devices have undergone extensive laboratory testing, only a few have proved sufficiently reliable, effective, and safe to be applied to man. The first among these was the auxiliary ventricle. This device was used in only two patients, both with endstage heart disease. Although neither was a long-term survivor, the device effectively augmented arterial pressure in diastole, reduced systolic arterial and left atrial pressure, and increased cardiac output. However, clotting within the device, blood-element destruction with bleeding, the major thoracotomy required to insert it, and the availability of in systemic arterial oxygenation saturation, and a fall in systemic arteriovenous oxygen difference after periods of counterpulsation ranging from 23 to 5J2 hours. Two of these patients subsequently died within 4 weeks, from progression of their disease; the remaining patient at the time of the report wvas alive and well after 16 months. Jacobey also has used counterpulsation for a period of 2 hours to treat 14 patients with severe angina pectoris secondary to three-vessel coronary disease. Nine of 13 patients available for evaluation (one patient died of a cerebrovascular accident) were improved symptomatically as judged by a decrease in frequency of pain and improvement in treadmill exercise tolerance. Eight of 11 patients studied with coronary arteriography had findings to suggest more coronary artery vessels were filling after counterpulsation than before.
These results, while encouraging, must be considered in association with the limitations of the method. First, the period over which counterpulsation may be applied is relatively short due to the blood-element destruction resulting from the high shear rates in the pump and cannulae. Clotting in the pump itself occurs after several hours despite systemic heparinization. A patent peripheral arterial system is a prerequisite for application, and local complications from arterial cannulation are a definite hazard.
Intraaortic Balloon Pump (IABP)
This approach, described initially by Moulopoulos and co-workers in 1962, employs a nonocclusive catheter-balloon system placed retrograde through a femoral artery into the descending thoracic aorta just distal to the left subclavian artery.5 Phasing of the device is accomplished by an external console utilizing the ECG to trigger inflation of the balloon during ventricular diastole and deflation during ventricular systole. Although carbon dioxide was used to inflate the original balloon, this has been replaced by helium because its low viscosity allows extremely rapid movement of gas in and out of the balloon.
The theoretical basis of the intraaortic balloon has been analyzed by Laird and associates.64 Briefly, these investigators pointed out that the original single-segment balloon tends to inflate at the ends first, with the middle inflating last. If the balloon were occlusive, blood would be trapped between the ends, and its pumping effectiveness impaired. Also, persistent contact with the aortic wall in these circumstances could lead to intimal damage or more serious sequelae. For these reasons, these investigators have developed a balloon with three compartments which will inflate in the middle first and then at the ends simply by making the hole in the middle compartment larger than the end holes.
Of all the types of MCA employed clinically, IABP has received the most extensive use. Kantrowitz and his associates were the first to apply the single-segment polyurethane balloon in the treatment of patients with CS-MI. 15 In their recent report on 30 patients so treated, IABP reversed the shock syndrome in 25.28 Although hemodynamic and metabolic effects of IABP were not detailed, IABP apparently improved signs of peripheral perfusion, increased urine output, diminished pulmonary vascular congestion, and controlled metabolic acidosis. A survival rate of 45% (nine of 20 patients) was found in patients whose shock developed immediately following myocardial infarction. In contrast, no survival occurred in the 10 patients whose shock was delayed in its onset; thus overall survival was 30%. These findings suggested that the interval between myocardial infarction and onset of shock was critical to survival with IABP. Pumping was continued for as long as ---------------- originate about the catheter-balloon system. In one of our own cases, two small emboli xvere found at autopsy in the kidney and testicle; a second patient who is a long-term survivor has minor claudication in the limb through which the balloon was inserted. Blood-element destruction has not been a serious problem; platelet counts usually drop to about half the normal value with pumping. In our early experience, thrombocytopenia of significant proportions occurred in one case without bleeding and was treated with platelet transfusions. Since employing 10 cc low molecular-weight dextran at hourly intervals, clinically significant depression of the platelet count has not occurred. Uncontrolled bleeding, hemolysis, or plasma-protein degradation has not been encountered. Dynamic aortic patch approach represents an extension of the intraaortic balloon principle. Developed by Sujansky and co-workers, the device consists of a cigar-shaped flexible bladder made of silicone rubber and lined with Dacron.29 A conduit is led from the bladder to a control console for synchronizing inflation of the pump in a manner identical to the balloon pump. The bladder is implanted into a longitudinal incision in the descending thoracic aorta such that the inner Dacron surface of the bladder is in direct contact with the aortic lumen. Hemodynamic effects in experimental animals were similar to those obtained with an intraaortic balloon pump of similar size. Considerable problems were encountered with infection, thrombosis, and interruption of pseudointima formation by pumping action of the device. Recently, the device has received its first clinical test in a patient with end-stage heart disease.67
Systems for External Regional Pressure Variation Synchronous regional pressure variation is a technic in which pressure is varied over the extremities synchronously with the heartbeat.10' 25 During ventricular systole, the limbs are exposed to a negative pressure of up to -50 mm Hg, thus pulling arterial blood into the extremities, lowering central aortic pressure, and facilitating left ventricular emptying.
Circulation, Volume XLV, Negative pressure is converted abruptly to a positive phase exposing the limbs to a maximum positive pressure of 200 mm Hg during diastole. The positive pressure has the combined effect of producing counterpulsation in the arterial circulation and forcing venous blood back to the heart during diastole. Dennis et al. were the first to apply this principle by employing a lower-body sleeve to experimental animals. 68 Soroff and co-workers have extended the technic to man with a device consisting of two large water-filled sleeves placed about the legs and encased in an airtight seal. ' an intraventricular cardiac balloon pump,72 and the Anstadt cup.13 Of these, the last device has been evaluated the most extensively in experimental animals and in clinical trials. This form of mechanical ventricular assistance (MVA) consists of a rigid cup lined with an inner silastic sleeve bonded to the apex and rim of the cup. The cup is placed over the heart and positive and negative pressures introduced into the space between the sleeve and the cup, thus producing direct cardiac compression. Gentle suction through a separate channel at the apex of the cup keeps the heart firmly in place. MVA is effective in the presence of ventricular fibrillation or can be synchronized through the ECG to the beating heart. Observations on experimental animals in ventricular fibrillation have shown that arterial pressure and cardiac output can be maintained at well above 50% of control valves in most instances.6 Clinical trials in 20 patients have included patients with cardiac arrest from primary myocardial disease and myocardial infarction, and a few in whom MVA was applied as a means of preserving donor kidneys.26 Arterial pressure was restored in most instances to near normal levels, and cardiac output reached as high as 5.2 liters/min. Duration of pumping ranged from 1 to 10 hours. There was only one short-term survivor; the remainder died from the consequences of their primary disease.
The major advantage of this method appears to be its effectiveness in the presence of ventricular fibrillation, the utilization of the vascular system of the patient, and the extended time over which it can be employed. Nonetheless, it requires a major thoracotomy which would appear justified only as a holding action pending complete heart replacement, or excision of donor organs.
Criteria for Discontinuing MCA Indications for discontinuing MCA fall into three general categories: (1) The time limit beyond which a particular form of MCA results in serious blood-element destruction has been approached or exceeded, or the device has produced a serious, unforeseen complication requiring its discontinuation. ( 2) The condition of the patient has deteriorated and recovery is impossible. (3) hours ( fig. 7) . Seven patients have been longterm survivors with follow-up of 2-16 months. These include three patients receiving bypass grafts alone, two with bypass grafts and myocardial resection, one patient with bypass grafts and mitral replacement, and one patient with infaretectomy alone. One late death has occurred due to abdominal infection following gastric surgery. 74-7 6 In an effort to define criteria in the selection of patients for surgery, the angiograms were reviewed and the findings compared with 7) . The most common combinationi of lesions was involvement of the right and left anterior descending coronary arteries with the circumflex or circumflex marginal branches providing the major source of blood supply to the myocardium.
Comment
The clinical use of MCA has been restricted largely to patients with severe left ventricular dysfunction following open-heart surgery or myocardial infarction, usually after all other therapy has failed. The results, though limited, have shown clearly that certain of these devices will support the circulation safely and effectively in such patients for a varying period of time. In our own institution, IABP has become standard therapy in patients with CS-MI. It has become clear that IABP alone will probably not salvage more than 20-30% of such patients. When IABP is combined with emergency angiography and acute revascularization, about 40% of patients can be saved. In the majority, however, total cardiac replacement appears necessary because myocardial damage is too extensive to be reversed by any other surgical technic. Other therapeutic roles for MCA are being investigated both clinically and experimentally (table 2), and it is in this group that the greatest application of MCA as a therapeutic tool may ultimately be found.
A number of problems may be identified in Sixth, assessment of the efficacy of a device is hindered by variability in selection of criteria among investigators for evaluating the performance of a device. This problem is compounded further by the instability of the clinical situation to which MCA is often applied and the difficulty in determining whether the device itself is responsible for clinical improvement or deterioration, or in fact has had any effect at all. Furthermore, data on possible side effects of a device are often lacking. Lastly, development of new, preferably noninvasive methods to quantitate and regionalize coronary blood flow, to size myocardial infarets, and to separate normal, ischemic, and n-ecrotic tissue is necessary in selecting patients for MCA and evaluating its influence on coronary blood flow and ventricular contraction.
None of these problems is insoluble, but time, proper funding, ingenuity, and dedication will be required for their solution. As the answers become available, the role of MCA and its impact in cardiovascular disease will become defined.
